Cytokinetics Reports Second Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) reported total revenues for the second quarter of 2017 were $3.1 million, compared to $5.8 million, during the same period in 2016. Net loss for the second quarter was $29.1 million, or $0.60 per share, respectively, compared to a net loss for the same period in 2016 of $11.6 million, or $0.29 per share. As of June 30, 2017, cash, cash equivalents and investments totaled $332.1 million.